Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression

Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204-1212.

Publication Type:

Journal Article

Authors:

Waziry, R; Hajarizadeh, B.; Grebely, J.; et, al

Source:

J Hepatol, Volume 67, Issue 6, p.1204-1212 (2017)

Cited On:

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

Export Citation:

RIS Format

Top